<DOC>
	<DOCNO>NCT02239614</DOCNO>
	<brief_summary>The potential synergistic effect administer 2 dengue vaccine candidate previously show safe immunogenic human evaluate study . A prime-boost study tetravalent dengue virus purify inactivated vaccine ( TDENV-PIV ) alum tetravalent dengue live attenuate virus ( TDENV-LAV ) vaccine Formulation 17 ( F17 ) gather data help good understand human immune response dengue vaccination infection .</brief_summary>
	<brief_title>TDENV PIV LAV Dengue Prime-boost Strategy</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<criteria>1 . Male female 18 49 year age ( inclusive ) time consent 2 . Able provide write informed consent 3 . Healthy establish medical history clinical examination enter study 4 . Able willing comply requirement protocol ( eg , document event memory aid , return followup visit , etc . ) 5 . Female subject nonchildbearing potential ( nonchildbearing potential define either current tubal ligation least 3 month prior enrollment history hysterectomy , ovariectomy , postmenopause ) 6 . Female subject breastfeeding agrees breastfeed 3 month last vaccination 7 . Female subject childbearing potential may enrol study , subject : 1 . Practiced adequate contraception 30 day prior vaccination , 2 . A negative urine pregnancy test day vaccination , 3 . Agreed continue adequate contraception 3 month completion vaccination series . 1 . Use investigational nonregistered product ( drug vaccine ) study vaccine period start 30 day precede first dose study vaccine and/or plan use study period 2 . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug period start 180 day prior first vaccine dose 1 . For corticosteroid , mean prednisone ≥ 20 mg/d equivalent 2 . Inhaled topical steroid allow 3 . Planned administration administration vaccine/product foreseen study protocol period start 14 day schedule dose investigational product 4 . Planned administration flavivirus vaccine entire study duration 5 . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) 6 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) 7 . Family history congenital hereditary immunodeficiency 8 . History , current , autoimmune disease 9 . History reaction hypersensitivity likely exacerbate component vaccine relate study procedure 10 . Major congenital defect serious chronic illness 11 . History neurological disorder seizure . ( except childhood febrile seizure ) 12 . Acute disease and/or fever ( oral body temperature ≥ 100.4°F/38.0°C ) time enrollment ( subject minor illness , ie , mild diarrhea , mild upper respiratory infection , etc , without fever , may enrol discretion investigator ) 13 . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal functional abnormality , determine physical examination laboratory screen test 14 . Administration immunoglobulins and/or blood product period start 90 day precede first dose study vaccine plan administration study period 15 . History chronic alcohol and/or drug abuse 16 . Pregnant breastfeed female female planning become pregnant planning discontinue contraceptive precaution 17 . A plan move location prohibit participate trial prior study end participant 18 . Subject seropositive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immunodeficiency virus antibody ( antiHIV ) 19 . Safety laboratory test result outside acceptable value screen : 1 . &gt; 110 % upper limit normal ( ULN ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , creatinine , serum urea nitrogen ( SUN ) bilirubin ( total direct ) 2 . &lt; 100 % low limit normal ( LLN ) &gt; 120 % ULN hemoglobin , hematocrit platelet count 3 . &lt; 75 % LLN &gt; 110 % ULN total white blood cell count ( WBC ) 20 . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dengue fever</keyword>
	<keyword>dengue</keyword>
</DOC>